Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C

Trial Profile

Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Most Recent Events

    • 11 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018.
    • 11 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
    • 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top